CoChat

INTRAVITREAL BEVACIZUMAB (AVASTIN) TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

EMERSON, M VAUGHN, LAUER, ANDREAS K., FLAXEL, CHRISTINA J., WILSON, DAVID J., FRANCIS, PETER J., STOUT, J TIMOTHY, EMERSON, GEOFFREY G., SCHLESINGER, THOMAS K., NOLTE, SUSAN K., KLEIN, MICHAEL L. · 2007 · Retina
Cited by 170

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

PURPOSE: To report the change in visual acuity and central retinal thickness by optical coherence tomography (OCT) after intravitreal injections of bevacizumab for the treatment of neovascular age-related macular degeneration (AMD). METHODS: A retrospective case series in a university-based practice evaluated patients with subfoveal choroidal neovascularization (CNV) due to AMD. Patients received intravitreal injections (1.25 mg) of bevacizumab and were monitored monthly with determination of best-corrected ETDRS visual acuity and OCT for persistence of retinal thickening. Eyes were retreated on an "as needed" basis, defined by presence of intraretinal or subretinal fluid. Patients were monitored every 2 months to 3 months for persistence of angiographic leakage. RESULTS: Seventy-nine eyes of 74 consecutive patients received the initial injection of bevacizumab between August 1, 2005, and January 30, 2006. Sixty-eight eyes (86%) of 64 patients had at least 3 months of follow-up. Mean central retinal thickness +/- SD decreased from 304 +/- 83 microm at baseline to 237 +/- 105 microm at 3 months (P = 0.00002). Mean ETDRS visual acuity gained 4 letters from 20/100 at baseline to 20/80-1 at 3 months (P = 0.040). Twenty eyes (25%) appeared to have a sustained response to a single injection and did not require further injections through 3 months. Two patients had a potentially drug-related adverse event (ischemic stroke and myocardial infarction). No serious injection-related adverse events occurred. CONCLUSIONS: Intravitreal bevacizumab injection affects a rapid decrease in retinal thickness to normal or near-normal levels and improvement in visual acuity in eyes with CNV due to AMD. The sustainability of changes in retinal thickness and visual acuity in response to bevacizumab treatment warrant further investigation and long-term follow-up.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/iae.0b013e31804b3e15

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 170

Metadata

Authors
EMERSON, M. V., LAUER, A. K., FLAXEL, C. J., WILSON, D. J., FRANCIS, P. J., STOUT, J. T., EMERSON, G. G., SCHLESINGER, T. K., NOLTE, S. K., & KLEIN, M. L.
Venue
Retina
Published
2007-04
Volume
27
Issue
4
Pages
439-444
ISSN
0275-004X (ISSN-L)
OpenAlex
W2055385676
Cited by
170
References
4
FWCI
33.52
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: INTRAVITREAL BEVACIZUMAB (AVASTIN) TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. https://app.cochat.ai/papers/10.1097/iae.0b013e31804b3e15
The paper
EMERSON, M. V., LAUER, A. K., FLAXEL, C. J., WILSON, D. J., FRANCIS, P. J., STOUT, J. T., EMERSON, G. G., SCHLESINGER, T. K., NOLTE, S. K., & KLEIN, M. L. (2007). INTRAVITREAL BEVACIZUMAB (AVASTIN) TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina. https://doi.org/10.1097/iae.0b013e31804b3e15

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.